Fintel reports that on April 4, 2025, Oppenheimer downgraded their outlook for RXO (NYSE:RXO) from Outperform to Perform.

My grandfather J. Robert Oppenheimer shared the first principle of nuclear weapons: The only safety from them is in ...

Christopher Nolan ’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had ...

The early reactions to Ryan Coogler's Sinners are out, and people are raving about the director's bold and audacious vision.

Investors should consider defensively oriented consumer stocks over disrectionary shares after President Trump's latest ...

Oppenheimer analyst Scott Schneeberger maintained a Buy rating on XPO (XPO – Research Report) today and set a price target of $142.00. The ...

The action "jolts forward" when an outsider (Moses Ingram) somehow enters the bunker, said Danny Leigh in the Financial Times ...

Robert Downey Jr rebuilt his career with Marvel’s Iron Man (in a cave with a box of scraps) but it’s not where he did his ...

Oppenheimer raised the firm’s price target on AT&T to $32 from $27 and keeps an Outperform rating on the shares. The firm cites better free ...

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...